Social phobia: Diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment

Journal of Affective Disorders

Volumn 60, Issue 1, 2000, Pages 61-74

  Brunello, N ^a,b   Den Boer, J A ^c   Judd, L L ^d   Kasper, S ^e   Kelsey, J E ^f   Lader, M ^g   Lecrubier, Y ^h   Lepine, J P ⁱ   Lydiard, R B ^j   Mendlewicz, J ^k   Montgomery, S A ^l   Racagni, G ^a,m   Stein, M B ⁿ   Wittchen, H U ^o  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Sect Clin Psychopharmacology S   (United Kingdom)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HÔPITAL FERNAND WIDAL   (France)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k ERASME HOSPITAL   (Belgium)

^l Science and Technology   (United Kingdom)

^m IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

more..

Author keywords

Anxiety disorders; Comorbidity; Paroxetine; Social phobia; SSRI

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BUSPIRONE; CLONAZEPAM; METOPROLOL; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NADOLOL; PAROXETINE; PHENELZINE; PLACEBO; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE;

BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL DISORDER; REVIEW; SOCIAL PHOBIA;

EID: 0033899945     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00140-8     Document Type: Article

References (99)

1. 4th ed Diagnostic and Statistical Manual of Mental Disorders. 1994;416-417 American Psychiatric Press, Washington, DC.
2. Amies P.L., Gelder M.G., Shaw P.M. Social phobia: a comparative clinical study. Br. J. Psychiatry. 142:1983;174-179.
3. Anderson C.A., Harvey R.J. Discriminating between problems in living: an examination of measures of depression, loneliness, shyness and social anxiety. J. Soc. Clin. Psychol. 6:1988;482-491.
4. Angst J., Dobler-Mikola A. The Zurich study - V. Anxiety and phobia in young adults. Eur. Arch. Psychiatry Neurol. Sci. 234:1991;408-418.
5. Bailly D. The role of beta-adrenoceptor blockers in the treatment of psychiatric disorders. CNS Drugs. 5:(2):1996;115-136.
6. Beidel D.C., Turner S.M., Dancu C.V. Physiological, cognitive, and behavioral aspects of social anxiety. Behav. Res. Ther. 23:1985;109-117.
7. Biederman J., Rosenbaum J.F., Hirschfeld D.R. Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders. Arch. Gen. Psychiatry. 47:1990;21-26.
8. Bisserbe J.C., Weiller E., Boyer P., Lepine J.P., Lecrubier Y. Social phobia in primary care: level of recognition and drug use. Int. Clin. Psychopharmacol. 11:(Suppl. 3):1996;25-28.
9. Bland R.C., Orn H., Newman S.C. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr. Scand. 77:(Suppl. 338):1988;24-32.
10. Bourdon K.H., Boyd J.H., Rae D.S., Burns B.J., Thompson J.W., Locke B.Z. Gender differences in phobias: results of the ECA community survey. J. Anxiety Disord. 2:1988;227-241.
11. Bourdon K.H. Social phobia: an overview of treatment strategies. J. Clin. Psychiatry. 54:1993;165-171.
12. Bouwer C., Stein D.J. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J. Affect. Disord. 49:1998;79-82.
13. Burke K.C., Burke J.D., Regier D.A., Rae D.S. Age at onset of selected mental disorders in five community populations. Arch. Gen. Psychiatry. 47:1990;511-518.
14. Burns L.E. The epidemiology of fears and phobias in general practice. J. Intern. Med. Res. 8:(Suppl. 3):1980;1-8.
15. 2 challenge test in patients with social phobia. Psychiatry Res. 71:1997;41-48.
16. Caspi A., Elder G.H., Bem D.J. Moving away from the world: life-course patterns of shy children. Dev. Psychol. 24:1988;824-831.
17. Chaterjee S., Sunitha T.A., Velayudhan A., Khanna S. An investigation into the psychobiology of social phobia: personality domains and serotonergic function. Acta Psychiatr. Scand. 95:1997;544-550.
18. Clark D.B., Agras W.S. The assessment and treatment of performance anxiety in musicians. Am. J. Psychiatry. 148:1991;598-605.
19. Davidson J.R.T., Hughes D.L., George L.K. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol. Med. 23:1993;709-718.
20. Davidson J.R.T., Potts N.L.S., Richichi E.A., Krishnan R., Ford S.M., Smith R., Wilson W.H. Treatment of social phobia with clonazepam and placebo. J. Clin. Psychopharmacol. 13:1993;423-428.
21. Davidson J.R.T., Hughes D.L., George L.K. The boundary of social phobia: exploring the threshold. Arch. Gen. Psychiatry. 51:1994;975-983.
22. Fahlen T., Nilsson H.L., Borg K., Humble M., Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr. Scand. 92:1995;351-358.
23. Gelertner C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., Bartko J.J. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch. Gen. Psychiatry. 48:1991;938-945.
24. Heimberg R.G., Liebowitz M.R., Hope D.A., Schneier F.R., Holt C.S., Welkowitz L.A., Juster H.R., Campeas R., Bruch M.A., Cloitre M., Fallon B., Klein D.F. Cognitive behavioral group therapy vs. phenelzine therapy for social phobia 12-week outcome. Arch. Gen. Psychiatry. 55:1998;1133-1141.
25. Katzelnick D.J., Kobak K.A., Greist J.H., Jefferson J.W., Mantle J.M., Serlin R.C. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. J. Psychiatry. 152:(9):1995;1368-1371.
26. Kelsey J.E. Venlafaxine in social phobia. Psychopharmacol. Bull. 31:1995;767-771.
27. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.-U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States; results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 51:1994;8-19.
28. Kessler R.C., Stein M.B., Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am. J. Psychiatry. 155:(5):1998;613-619.
29. Lecrubier Y., Weiller E. Comorbidities in social phobia. Int. Clin. Psychopharmacol. 12:(Suppl. 6):1997;S17-S21.
30. Lepine J.P., Lellouch J. Classification and epidemiology of social phobia. Eur. Arch. Psychiatry. 244:1995;290-296.
31. Lepine J.P., Pelissolo A. Comorbidity and social phobia: clinical and epidemiological issues. Int. Clin. Psychopharmacol. 11:(Suppl. 3):1996;35-41.
32. Lepola U., Koponen H., Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry. 27:1994;186-188.
33. Liebowitz M.R., Gorman J.M., Fyer A.J., Klein D.F. Social phobia: review of a neglected anxiety disorder. Arch. Gen. Psychiatry. 42:1985;729-736.
34. Liebowitz M.R., Fyer A.J., Gorman J.M., et al. Specificity of lactate infusions in social phobia versus panic disorders. Am. J. Psychiatry. 142:(8):1985;947-950.
35. Liebowitz M.R., Schneier F., Campeas R., Hollander J., Fyer A., Gorman J., Papp L., Davies S., Gully R., Klein D.F. Phenelzine vs. atenolol in social phobia. A placebo-controlled comparison. Arch. Gen. Psychiatry. 49:1992;290-300.
36. Lott M., Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Katz R.J., Schaettle S.C. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 17:1997;255-260.
37. Lydiard R.B., Laraia M.T., Howell E.F., Ballenger J.C. Alprazolam in the treatment of social phobia. J. Clin. Psychiatry. 49:1988;17-19.
38. Lydiard R.B., Falsetti S.A. Treatment options for social phobia. Psychiatr. Ann. 25:1995;570-576.
39. Lydiard R.B. The role of drug therapy in social phobia. J. Affect. Disord. 50:(Suppl. 1):1998;S35-39.
40. Magee W.J., Eaton W.W., Wittchen H.-U., McGonagle K.A., Kessler R.C. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch. Gen. Psychiatry. 53:1996;159-168.
41. McCann U.D., Slate S.O., Geraci M., Roscow-Terrill D., Uhde T.W. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacology. 16:1997;229-237.
42. Merikangas K., Angst J., Eaton W., Canino G., Rubio-Stipec M., Wacker H., Wittchen H.-U., Andrade L., Essau C.A., Kraemer H., Robins L., Kupfer D. Comorbidity and boundaries of affective disorders with anxiety disorders and substance abuse: results of an international task force. Br. J. Psychiatry. 168:(Suppl. 30):1996;49-58.
43. Mullaney J.A., Trippet C.J. Alcohol dependence and phobias: clinical description and relevance. Br. J. Psychiatry. 135:1979;565-573.
44. Munjack D.J., Baltazar P.L., Bohn P.B., Cabe D.D., Appleton A.A. Clonazepam in the treatment of social phobias: a pilot study. J. Clin. Psychiatry. 51:(Suppl. 5):1990;35-40.
45. Noyes R. Jr., Moroz G., Davidson J.R., Liebowitz M.R., Davidson A., Siegel J., Bell J., Cain J.W., Curlik S.M., Kent T.A., Lydiard R.B., Mallinger A.G., Pollack M.H., Rapaport M., Rasmussen S.A., Hedges D., Schweizer E., Uhlenhuth E.H. Moclobemide in social phobia: a controlled dose-response trial. J. Clin. Psychopharmacol. 17:1997;247-254.
46. Nutt D., Montgomery S.A. Moclobemide in the treatment of social phobia. Int. Clin. Psychopharmacol. 11:1996;77-82.
47. Ontiveros A., Fontaine R. Social phobia and clonazepam. Can. J. Psychiatry. 35:1990;439-441.
48. Papp L.A., Gorman J.M., Liebowitz M.R., Fyer A.J., Cohen B.S., Klein D.F. Epinephrine infusions in patients with social phobia. Am. J. Psychiatry. 145:(6):1988;733-736.
49. Papp L.A., Klein D.F., Schneier F., Cole R., Liebowitz M.R., Hollander E., Fyer A.J., Jordan F., Gorman J.M. Diagnostic and substance specificity of carbon-dioxide-induced panic. Am. J. Psychiatry. 150:1993;250-257.
50. Phillips S.D., Bruch M.A. Shyness and dysfunction in career development. J. Counsel. Psychol. 35:1988;159-165.
51. Potts N.L., Davidson J.R., Krishnan K.R., Doraiswamy P.M. Magnetic resonance imaging in social phobia. Psychiatry Res. 52:1994;35-42.
52. Potts N.L.S., Davidson J.R.T., Krishnan K.R.R., Doraiswamy P.M., Ritchie J.C. Levels of urinary free cortisol in social phobia. J. Clin. Psychiatry. 52:(11, Suppl.):1991;41-42.
53. Rapaport M.H., Stein M.B. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia. Anxiety. 1:1994;50-53.
54. Regier D.A., Narrow W.E., Rae D.S. The epidemiology of anxiety disorders: The Epidemiologic Catchment Area (ECA) experience. J. Psychiatr. Res. 24:(Suppl. 2):1990;3-14.
55. Reich J., Noyes R., Yates W. Anxiety symptoms distinguishing social phobia from panic and generalized anxiety disorders. J. Nerv. Ment. Dis. 176:1988;510-513.
56. Reich J., Noyes R. Jr., Yates W. Alprazolam treatment in avoidant personality traits in social phobic patients. J. Clin. Psychiatry. 50:1989;91-95.
57. Reiter S.R., Pollack M.H., Rosenbaum J.F., Cohen L.S. Clonazepam for the treatment of social phobia. J. Clin. Psychiatry. 51:1990;470-472.
58. Robins L.N., Helzer J.E., Crougham R., Williams J.B., Spitzer R.L. NIMH Diagnostic Interview Schedule: Version III. 1981;National Institute of Mental Health, Rockville, MD.
59. Robins L.N., Helzer J.E., Croughan J., Ratcliff K.S. National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristic and validity. Arch. Gen. Psychiatry. 38:1981;381-389.
60. Rosenbaum J.F., Biederman J., Bolduc E.A. Comorbidity of parental anxiety disorders as risks for childhood onset in inhibited children. Am. J. Psychiatry. 149:1992;475-481.
61. Ross J. Social phobia: the consumer's perspective. J. Clin. Psychiatry. 54:(Suppl.):1993;5-9.
62. Sanderson W.C., Di Nardo P.A., Rapee R.M., Barlow D.H. Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. J. Abnorm. Psychol. 99:1990;308-312.
63. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., Weissman M.M. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry. 49:(4):1992;282-288.
64. Schneier F.R., Chin S.J., Hollander E., Liebowitz M.R. Fluoxetine in social phobia. J. Clin. Psychopharmacol. 12:(1):1992;62-64.
65. Schneier F.R., Juster H.R., Heimberg R.G., et al. Diagnosis and treatment of social phobia. J Pract Psychiatry Behav Health. 2:1992;94-104.
66. Schneier F.R., Jihad B.S., Campeas R., Fallon B.A., Hollander E., Coplan J., Liebowitz M.R. Buspirone in social phobia. J. Clin. Psychopharmacol. 13:1993;251-256.
67. Schneier F.R., Heckelman L.R., Garfinkel R., Campeas R., Fallon B.A., Gitow A., Street L., Del Bene D., Liebowitz M.R. Functional impairment in social phobia. J. Clin. Psychiatry. 55:(8):1994;322-331.
68. Schneier F.R. Clinical assessment strategies for social phobia. Psychiatr. Ann. 25:1995;550-553.
69. Schneier F.R., Goetz D., Campeas R., Fallon B., Marshall R., Liebowitz M.R. Placebo-controlled trial of moclobemide in social phobia. Br. J. Psychiatry. 172:1998;70-77.
70. Slaap B.R., van Vliet I.M., Westenberg H.G.M., Den Boer J.A. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J. Affect. Disord. 39:1996;13-19.
71. Solyom L., Ledwidge B., Solyom C. Delineating social phobia. Br. J. Psychiatry. 149:1986;464-470.
72. Stein M.B., Tancer M.E., Uhde T.W. Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders; comparison of patients with panic disorder and social phobia and normal control subjects. Arch. Gen. Psychiatry. 49:1992;311-317.
73. Stein M.B., Walker J.R., Forde D.R. Setting diagnostic thresholds for social phobia: consideration from a community survey of social anxiety. Am. J. Psychiatry. 151:1994;408-412.
74. Stein M.B., Delaney S.M., Chartier M.J., Kroft C.D., Hazen A.L. [3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers. Biol. Psychiatry. 37:1995;224-228.
75. Stein M.B., Chartier M.J., Hazen A.L., Kroft C.D., Chale R.A., Cote D., Walker J.R. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16:1996;218-222.
76. Stein M.B., Hauger H.L., Dhalla K.S., Chartier M.J., Asmundson G.J. Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia. Psychiatry Res. 59:1996;183-188.
77. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (Social Anxiety Disorders): a randomized controlled study. J. Am. Med. Assoc. 280:1998;708-713.
78. Tancer M.E., Stein M.B., Gelernter C.S., Uhde T.W. The hypothalamic-pituitary-thyroid axis in social phobia. Am. J. Psychiatry. 147:1990;929-933.
79. Tancer M.E., Mailman R.B., Stein M.B., Mason G.A., Carson S.W., Golden R.N. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety. 1:1994;216-223.
80. Tiihonen J., Kuikka J., Bergstrom K., Lepola U., Koponen H., Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am. J. Psychiatry. 154:1997;239-242.
81. Turner S.M., Beidel D.C., Larkin K.T. Situational determinants of social anxiety in clinic and nonclinic samples. Physiological and cognitive correlates. J. Consult. Clin. Psychol. 54:1986;523-527.
82. Van Ameringen M., Mancini C., Streiner D.L. Fluoxetine efficacy in social phobia. J. Clin. Psychiatry. 54:(1):1993;27-32.
83. Van Vliet I.M., den Boer J.A., Westenberg H.G. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur. Neuropsychopharmacol. 2:1992;21-29.
84. Van Vliet I.M., den Boer J.A., Westenberg H.G. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology. 115:1994;128-134.
85. Van Vliet I.M., Westenberg H.G.M., Slaap B.R., den Boer J.A., Ho Pian K.L. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol. Psychiatry. 42:1997;76-78.
86. Van Vliet I.M., den Boer J.A., Westenberg H.G., Pian K.L. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J. Clin. Psychiatry. 58:1997;164-168.
87. Versiani M., Mundim F.D., Nardi A.E., Liebowitz M.R. Tranylcypromine in social phobia. J. Clin. Psychopharmacol. 8:1988;279-283.
88. Versiani M., Nardi A.E., Mundim F.D., Alves A.B., Liebowitz M.R., Amrein R. Pharmacotherapy of social phobia; a controlled study with moclobemide and phenelzine. Br. J. Psychiatry. 161:1992;353-360.
89. Versiani M., Nardi A.E., Mundim F.D., Pinto S., Saboya E., Kovacs R. The long-term treatment of social phobia with moclobemide. Int. Clin. Psychopharmacol. 11:(Suppl. 3):1996;83-88.
90. Versiani M., Amrein R., Montgomery S.A. Social phobia - long-term treatment outcome and prediction of response - a moclobemide study. Int. Clin. Psychopharmacol. 12:(5):1997;239-254.
91. Wacker H.R., Müllejans R., Klein K.H., Battegay R. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the Composite International Diagnostic Interview (CIDI). Int. J. Methods Psychiatr. Res. 2:(2):1992;91-100.
92. Walker J.R., Stein M.B. Epidemiology. Stein M.B. Social Phobia. Clinical and Research Perspectives. 1995;43-75 American Psychiatric Press.
93. Weiller E., Bisserbe J.C., Boyer P., Lépine J.P., Lecrubier Y. Social phobia in general health care. An unrecognised undertreated disabling disorder. Br. J. Psychiatry. 168:1996;169-174.
94. Wells J.E., Bushnell J.A., Hornblow A.R. Christchurch psychiatric epidemiology study. I. Methodology and lifetime prevalence for specific mental disorders. Aust. NZ J. Psychiatry. 23:1989;315-326.
95. Wittchen H.-U., Essau C.A., Zerssen D., von Krieg C.J., Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur. Arch. Psychiatry Clin. Neurosci. 241:1992;247-258.
96. Wittchen H.-U., Beloch E. The impact of social phobia on quality of life. Int. Clin. Psychopharmacol. 11:1996;15-24.
97. Wittchen H.-U., Zhao S., Abelson J.M., Abelson J.L., Kessler R.C. Reliability and procedural validity of UM-CIDI DSM-III-R phobic disorders. Psychol. Med. 26:(6):1996;1169-1177.
98. Wittchen H.-U., Nelson C.B., Lachner G. Prevalence of mental disorders and psychological impairments in adolescents and young adults. Psychol. Med. 28:1998;109-126.
99. Composite International Diagnostic Interview (CIDI). 1990;World Health Organization, Division of Mental Health, Geneva.